Tezepelumab Cuts COPD Exacerbation Rate in High-Risk Population: COURSE Trial Highlights with Dave Singh, MD

While tezepelumab, the novel thymic stromal lymphopoietin (TSLP) inhibitor, missed the phase 2a study's primary endpoint, reaching a nonsignificant numerical reduction of 17% in the annual rate of moderate to severe COPD exacerbations vs placebo, outcomes in the study's high-risk population, participants with blood eosinophil count levels of 150 cells/µL or greater, were much more promising, lead study investigator Dave Singh, MD, professor of respiratory pharmacology at the University of Manchester, in Manchester, England, told Patient Care®. He highlights all the findings here, including the statistically significant reduction in exacerbations of 37% over the 52-week treatment period in this vulnerable subgroup.

Singh presented findings on behalf of the COURSE study group from Tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD): efficacy and safety from the phase 2a COURSE study at the 2024 American Thoracic Society International Conference, May 17-22, 2024, in San Diego, CA.